Skip header and navigation

5 records – page 1 of 1.

5-Aminosalicylate (5-ASA)

http://libcat.nshealth.ca/permalink/chpams35397
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1483
Available Online
View Pamphlet
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.) : digital, PDF file
Subjects (MeSH)
Colitis - drug therapy
Crohn Disease - drug therapy
Inflammatory Bowel Diseases - drug therapy
Other Subjects
Colitis
Crohn's disease
Inflammatory bowel diseases
Abstract
5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn’s colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.
Responsibility
Prepared by: Jennifer Stewart, RN; Gastroenterology
Prepared by: Kaleigh MacIsaac, B.ScPharm; Gastroenterology
Revised by: Alison Harding, B.Sc.
Revised by: Phyllis Durning, RN
Pamphlet Number
1483

Adalimumab (Humira®) therapy

http://libcat.nshealth.ca/permalink/chpams35127
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1207
Available Online
View Pamphlet
Your healthcare provider feels that treatment with adalimumab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Adalimumab
Inflammatory Bowel Diseases - drug therapy
Other Subjects
Inflammatory bowel diseases
Specialty
Medications
Abstract
Your healthcare provider feels that treatment with adalimumab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Responsibility
Prepared by: Division of Gastroenterology
Pamphlet Number
1207

Azathioprine (Imuran®) therapy

http://libcat.nshealth.ca/permalink/chpams35565
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2015.
Pamphlet Number
1079
Available Online
View Pamphlet
This pamphlet provides information about azathioprine (Imuran®) therapy, an immunosuppressive drug. The pamphlet explains what azathioprine is, how well it works, as well as potential minor and major side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2015
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.): digital, PDF file
Subjects (MeSH)
Azathioprine
Immunosuppressive Agents
Other Subjects
Immunosuppressive agents
Specialty
Gastroenterology
Abstract
This pamphlet provides information about azathioprine (Imuran®) therapy, an immunosuppressive drug. The pamphlet explains what azathioprine is, how well it works, as well as potential minor and major side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
Responsibility
Updated by: Jennifer Stewart, RNCCRP; Tim Mombourquette (GI Research Student)
Pamphlet Number
1079

Infliximab (Remicade) therapy

http://libcat.nshealth.ca/permalink/chpams34944
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1140
Available Online
View Pamphlet
Your healthcare provider feels that treatment with infliximab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Inflammatory Bowel Diseases - drug therapy
Infliximab
Other Subjects
Inflammatory bowel diseases
Infliximab
Abstract
Your healthcare provider feels that treatment with infliximab may be helpful in managing your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
Responsibility
Prepared by: Division of Gastroenterology
Pamphlet Number
1140

Vedolizumab (Entyvio®) therapy

http://libcat.nshealth.ca/permalink/chpams35620
Nova Scotia Health Authority. Central Zone. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2016.
Pamphlet Number
1623
Available Online
View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. In this pamphlet you will find information to help you make an informed decision about whether or not use this treatment. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2016
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Gastrointestinal Agents
Other Subjects
Crohn's disease
Gastrointestinal agents
Ulcerative colitis
Abstract
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. In this pamphlet you will find information to help you make an informed decision about whether or not use this treatment. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Responsibility
Prepared by: Allison Harding BSc & Jennifer Stewart RN, CCRP; Division of Gastroenterology
Pamphlet Number
1623

Revise Search

Narrow By